In plain terms

The claim being assessed: Metformin slows biological aging in non-diabetic humans and extends healthspan.

Where the evidence stands: Γ — Plausible mechanism. There is a believable biological story and partial support, but the causal step has not been demonstrated.

What this mechanism does: The evidence reviewed does not show this mechanism causing the outcome. That does not show it has no effect.

Strongest evidence for it: Overall Γ applies to SC3. Context-specific animal function/survival and genuine prevention of diabetes do not establish generalized human aging slowing. The strongest model results are retained at Ε within their tested settings, with dose, timing, sex, diet and statistical boundaries explicit.

What decisive evidence would look like

In plain terms, researchers would change the proposed cause, confirm it changed as intended, and measure a meaningful health outcome while checking other explanations. The result should be able to support or count against the claim.

Relative explanatory fit: Alternative ranked ahead

What this review means

Metformin has model geroprotection and human diabetes-prevention evidence; slowing general aging in people without diabetes remains unproved.

Implications for health and treatment: Overall Γ applies to SC3. Context-specific animal function/survival and genuine prevention of diabetes do not establish generalized human aging slowing. The strongest model results are retained at Ε within their tested settings, with dose, timing, sex, diet and statistical boundaries explicit.

Limits for individual care: 61 primary reports with 3 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness. The grade applies to the exact registered claim; stronger findings for narrower subclaims remain separate. No complete-paper audit or blinded calibration is claimed. This educational review does not establish an individual treatment recommendation.

Medical information notice: This review provides general health information, not medical advice. It cannot diagnose a condition or replace an individual discussion with a qualified clinician.

Source checking used bounded original primary abstract passages/status records and selected original partial-body passages. No complete-abstract or complete-paper audit, or independent scientific peer review, is claimed. Detailed access counts and limitations appear in the review.

A low grade is not an accusation. It means the causal work has not been done yet, which is the ordinary state of most actively studied mechanisms in biology.

At a glance

Sub-claims assessed separately

Figures

Explanatory figures summarizing this review. They carry no evidential weight of their own; where a figure and the review differ, the review governs.

Full assessment

From here the review is written for a technical reader: caps and thresholds, competing models, the independence basis, and the citation ledger.

Sources: 61 primary reports; claims: 65; verified: 65; unverified: 0. Verification is bounded attribution. Access: 3 partial-body and 58 bounded abstract/status examinations. Literature cutoff: 2026-10-09; source examination UTC date: 2026-10-10. No complete-paper audit or blinded calibration claimed. Adversarial review: Generated by Sol 6.1; adversarially reviewed by Claude Opus 5.5 (Anthropic) on 2026-10-14. 4 corrections applied (see ADVERSARIAL REVIEW AND APPROVAL). Status: Approved as revised.

AT A GLANCE

Metformin has model geroprotection and human diabetes-prevention evidence; slowing general aging in people without diabetes remains unproved.

Deciding experiment: Conduct a prespecified randomized non-diabetic older-human trial measuring durable clinical/function trajectories, with baseline metabolic strata, nutrition/weight monitoring and mechanistic engagement; keep disease-specific prevention and aging outcomes separate.

Belief versus evidence: Overall Γ applies to SC3. Context-specific animal function/survival and genuine prevention of diabetes do not establish generalized human aging slowing. The strongest model results are retained at Ε within their tested settings, with dose, timing, sex, diet and statistical boundaries explicit.

Best-supported rival: Context-specific metabolic and stress effects. A sufficiently long randomized non-diabetic aging/function study with prespecified baseline and nutritional controls would separate broad geroprotection from disease prevention, caloric effects and treatment-selection artifacts.

COMPETING MECHANISTIC MODELS

Rank 1: Context-specific metabolic and stress effects (Ε). Metformin can improve particular metabolic, disease or model outcomes without a uniform general-aging effect. DPP prevention and constrained animal functional/survival effects are causal. This does not prove broad human healthspan or all proposed stress pathways.

Rank 2: General human geroprotection (Γ). Modifying metformin-responsive pathways slows aging and improves healthspan in people without diabetes. Model lifespan/function, monkey outcomes and human mechanistic markers support plausibility. Human generalized aging trajectories are unestablished; exercise and model boundary results constrain robustness.

Rank 3: Diet/microbe-mediated model benefit (Γ). Altered intake or bacterial metabolism can explain selected lifespan effects. Worm bacterial/methionine dependencies and human appetite effects directly motivate this rival. They do not explain every specific mammalian pathway effect.

Rank 4: Selection in observational survival (Β). Treatment eligibility and disease/control differences can produce apparent mortality advantages. Diabetic observational comparisons change with follow-up and selection assumptions. This cannot negate randomized disease prevention or all model interventions.

The tournament does not alter the nominal level. Compatible pathways and flexible alternatives are not automatically proved by explaining observations.

FULL REVIEW

Registered claim and scope

Metformin slows biological aging in non-diabetic humans and extends healthspan.

The website claim hinges on SC3 at its stated scope; SC1 and SC2 are reported separately and cannot substitute for that claim.

Selection: remaining-priority list position 4 from the editorial list of 2026-10-09. No prior grade consulted; this is not independent blinded calibration.

Evidence and causal interpretation

Rubric fit: 06-metabolism-aging directly governs organismal-aging and healthspan claims. Specific molecular causality is distinguished from aging causality; SC2 deliberately scores constrained model outcomes rather than extrapolating them to SC3.

Metformin acts through experimentally studied pathways, including lysosomal PEN2/AMPK signaling, but pathway engagement is not the same proposition as slowing organismal aging. Ex vivo aged-human cell changes and epigenetic-clock findings are informative mechanism work without demonstrated general human functional benefit. [19] [21] [37]

Defined animal outcomes exceed biomarker-only evidence. The male-mouse experiment showed survival and fitness benefit at one exposure and shortened survival at a higher one; its second-strain result was nonsignificant. Worm effects depend on microbial/diet context, and fly and older-monkey studies add other constrained systems. No clock result is interpreted as literal years rejuvenated. [38] [22] [32] [18]

ITP should not be described as a simple immutable null. Its original metformin-alone log-rank analysis was nonsignificant, while a later Gehan reanalysis detected early male survival effects in the same data. That is statistical reinterpretation, not independent replication. The metformin/rapamycin comparison used historical rapamycin cohorts, leaving combination attribution limited. [48] [51]

DPP establishes genuine diabetes prevention in high-risk people without diabetes, including longer follow-up. It does not establish a slower general aging trajectory. In older-human exercise trials, metformin attenuated selected adaptations; MASTERS muscle-mass effects were significant while strength differences were not. Neither these boundaries nor nonrandomized diabetic survival comparisons prove universal benefit or harm. [10] [9] [7] [60] [59] [61]

HYPOTHESIS STATE EVALUATION FRAMEWORK (HSEF v5.3)

Consensus consistency validation — 9 October 2026

Cutoff: 2026-10-09. Provider artifacts: consensus-browser-response.md (verbatim, citation markers preserved), browser-thread.json, consensus-search-raw.json. Consensus thread: Metformin effects on human aging, Pro. The browser response correctly surfaced METFORAGING and distinguishes epigenetic biomarkers from healthspan in places. Its cited reviews and lifespan meta-analysis are discovery sources; primary claims below were checked against original reports. Separately, the protocol/preprint search surfaced an important non-peer-reviewed older-prediabetes frailty trial; it is recorded as supplemental, outside the original 61 reports.

Primary-source reconciliation

• PMID 42023167; DOI 10.1016/j.eclinm.2026.103874 (METFORAGING). Primary randomized pilot: 40 older non-diabetic people living with HIV randomized (19/21); 35 completed 96 weeks. Primary PhenoAge EAA between-group difference −1.02 years (95% CI −5.30 to 3.26; p=.627); no statistically significant between-group effects on epigenetic biomarkers. Original 61-source ledger does not contain this new 2026 paper; provider-discovered and within cutoff, but supplemental only. Small, disease-context pilot with imprecise null does not demonstrate healthspan extension.
• PMID 33428709; DOI 10.1093/gerona/glaa295 (DPP/DPPOS frailty). Original primary report already in source ledger, same group as diabetes-prevention follow-up. Frailty findings do not demonstrate broad geroprotection in non-diabetic adults; only selected older prediabetes population and functional frailty outcomes. Consensus’s older review citation to preliminary/unpublished DPPOS information is superseded by consulting this published original report.
• PMID 36281624; DOI 10.1111/acel.13733 (Parish & Swindell). Secondary source, not a primary comparison. Consensus-cited systematic review/meta-analysis of animal lifespan studies. It reports heterogeneous effects and no significant overall lifespan extension in mice or nematodes (with subgroup-specific worm signal). Absent from the frozen selected-records ledger, and excluded from the original primary-report count. It is a useful contradictory synthesis for SC2 but does not alter SC3.
• Supplemental outside-ledger finding: PMID 42620010; DOI 10.64898/2026.07.27.26359055; NCT02570672. Musi et al., medRxiv preprint (posted 2026-07-28; explicitly not peer reviewed), one-site 2-year randomized trial in older adults with prediabetes/glucose intolerance (145 randomized; 141 ITT). Registered protocol DOI 10.1093/gerona/glz069 specifies Fried frailty status/score as the primary endpoint and deficit-accumulation frailty index (FI) as secondary. Preprint reports no clear positive primary functional result: Fried score worsened in year 1 then stabilized; the year-1 effect was driven by weight-loss item, disappearing when that item was removed. Secondary FI decreased modestly (unadjusted −0.006±0.0026/year, p=.0222; BMI-adjusted −0.005±0.0024/year, p=.0446). This is a plausible narrow functional signal in older adults with dysglycemia, not evidence for the exact broad claim in SC3 (“non-diabetic humans” generally), not replication, and not peer reviewed. It cannot be treated as a primary threshold crossing. Any score recalculation that rests on this preprint would require confidence cap Low under the stated framework rule for non-peer-reviewed work; current score does not rely on it.

Claim/score judgement

Preregistered SC3 is broad non-diabetic human aging/healthspan, and the preregistered primary-subclaim aggregation must remain controlling. The prediabetes trial’s narrow secondary FI signal cannot establish broad generalization, while its registered Fried primary endpoint was not clearly positive. METFORAGING is a small biomarker-focused pilot with a wide null estimate; DPPOS is disease-prevention context and not generalized aging. Score remains Γ / Moderate; no patch proposed. Original totals remain 61 primary reports, 65 verified claims; the two new metformin publications are supplemental and do not inflate the original count. If later authorized to recalculate on the preprint, confidence must be Low if the final judgment rests on it; that is not proposed here.

This reconciles provider-discovered citations with original source records and protocols. It is not an independent blinded review. Consensus labels were not used to assign tier or score.

Primary record links

PMID 42023167 · PMID 33428709 · PMID 36281624 · PMID 42620010 · registered protocol, DOI 10.1093/gerona/glz069

This dated supplement adds source reconciliation to the original review. Its original narrative, registered scope, source inventory and grades remain historical records. No earlier adversarial approval has been verified for this edition at the supplement date. This provenance supplement has no separate approval and is not an independent or blinded adjudication. New sources described here are supplemental and are not counted in the original inventory.

Subclaim matrix and aggregation

Preregistered aggregation: primary-subclaim. Overall Γ applies to SC3. Context-specific animal function/survival and genuine prevention of diabetes do not establish generalized human aging slowing. The strongest model results are retained at Ε within their tested settings, with dose, timing, sex, diet and statistical boundaries explicit. Sensitivities: weakest-link Γ; primary-subclaim Γ; scope-matched Γ.

Decisive-perturbation inventory and causal tally

[1] Metformin improved survival/motor outcomes in an ALS worm model with pathway dependencies. A syndromic worm model does not establish general aging or human healthspan.

[2] Metformin/galantamine combinations improved selected muscle and survival phenotypes. Combination effects cannot be assigned to metformin alone or generalized to humans.

[7] Metformin attenuated selected aerobic-training and mitochondrial adaptations in older adults. This does not prove universal harm or absence of benefits outside the exercise context.

[8] DPPOS frailty analyses favored lifestyle but not metformin. Prediabetic enrollment and endpoint context do not resolve every aging outcome.

[10] DPP randomized metformin and lifestyle both prevented diabetes in high-risk nondiabetic participants. A real disease-specific preventive effect is not proof that metformin slows general aging.

[11] Metformin blunted selected exercise-related vascular adaptations. Treatment-by-exercise context is not universal longevity harm.

[18] Metformin-treated older male monkeys showed selected functional, structural and aging-indicator changes. Sex-specific nonhuman context and aging-clock shifts are not demonstrated human lifespan extension or literal years rejuvenated.

[19] PEN2/ATP6AP1 experiments identified a lysosomal metformin/AMPK mechanism with model genetic dependencies. Target/pathway causality is not organism-wide human aging causality.

[22] Metformin changed worm lifespan through bacterial metabolism and methionine-related context. Diet and bacterial-strain dependence challenge a uniform direct host-aging mechanism.

[23] Metformin restored aged rodent oligodendrocyte precursor/remyelination responses. Lesion repair is functional but does not establish global aging or human healthspan.

[30] Worm genetic work linked metformin longevity effects to lysosomal AMPK/TOR signaling. Pathway dependence in a model does not establish human mechanism necessity.

[32] Fly experiments linked metformin to muscle function/lifespan and AMPK/TOR pathways. Species and model context limit inference to humans.

[38] Metformin extended lifespan and improved fitness in a defined male-mouse experiment while a higher exposure shortened survival. The second strain's survival result was nonsignificant; concentration, sex and context boundaries prevent generalizing to human aging.

[46] Fischer-344 rat survival did not show a metformin longevity benefit under tested conditions. A regimen-specific null constrains robustness rather than proving all metformin aging effects absent.

[48] ITP's original analysis found no statistically significant metformin-alone lifespan benefit; combination survival improved. Later reanalysis detected a male early-survival signal; historical rapamycin controls do not isolate combination synergy.

[49] Late-life metformin shortened worm survival in a metabolic-plasticity context. Age-dependent model toxicity is not direct evidence of human lifespan harm.

[54] Presurgical breast-cancer metformin did not improve overall Ki67, with exploratory insulin-resistance heterogeneity. Subgroup interaction and a proliferation surrogate do not establish cancer prevention or aging benefit.

[55] A small nondiabetic trial reduced a colorectal aberrant-crypt-foci surrogate. A short surrogate trial is not cancer-incidence or lifespan proof.

[57] MYME did not improve breast-cancer progression-free survival with metformin addition. Chemotherapy combination in cancer is not a generalized aging intervention.

[58] MET-DIME improved selected diastolic Doppler measures without a clear peak-VO2 or SF36 difference. Imaging/physiology changes are not demonstrated broad functional healthspan.

[60] MASTERS found less exercise-induced muscle-mass gain with metformin in older adults. Strength differences were trends without statistical significance; muscle adaptation is not all aging outcomes. An erratum is attached.

Tally: 21 discriminating contrasts. Null and negative contrasts are discriminators, not positive threshold crossings. Reports and replications are not independent causal lines. The tally counts reports with discriminating intervention contrasts, including negative results; it is not a count of positive causal crossings. Shared parent trials and multiple manipulations within a study remain grouped.

Cap audit, precedence and Β/Γ/Δ boundary

Animal functional/survival interventions cross within defined model scopes, including constrained Ε. Human biomarkers do not cross the aging threshold. Animal positive results cannot supply the human claim, and one weak animal or observational leg does not negate the stronger constrained model case.

Universal six-cap audit: 1: In vitro evidence alone cannot exceed Γ; cell and biochemical findings do not establish human endogenous causality. 2: Pure association evidence cannot exceed Β; association-only presence/risk/reliability subclaims retain Β. 3: Overexpression in model systems caps at Γ for the broader claim; artificially engaged targets are not endogenous human necessity. 4: Biomarker change without functional/phenotypic change caps at Γ; clocks, concentrations and immune markers cannot replace functional outcomes. 5: Seeding or forced-transfer paradigms cap at Γ for endogenous propagation claims; injected spike, transferred IgG and forced model stimulation retain their model scope. 6: Familial/syndromic genetic findings remain scope-restricted; ALS/syndromic model mechanisms do not automatically establish general aging or sporadic human disease. None of these is reapplied to downgrade a genuinely convergent same-scope causal set.

Gamma hard-rule audit: Human associations and biomarker-only changes do not establish the broad causal claim. Model perturbations bind their tested species and phenotype, not an untested human scope. Positive treatment effects are checked for specific mechanism attribution; negative trials require target engagement before mechanistic falsification.

SC1 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: no. Metformin has specific experimentally demonstrated molecular/pathway effects, but aging attribution cannot be established by AMPK, redox, senescence or clock markers alone.

SC2 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: yes. Defined model interventions change survival/function in worms, flies and selected mammals. Ε is restricted to demonstrated species, genotype, timing and exposure; negative and toxic contexts prevent a universal model claim.

SC3 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: no. Non-diabetic high-risk people obtain genuine diabetes prevention, but this does not establish slower general aging or broad functional healthspan. Short biomarkers and diabetic observational survival cannot supply that missing clinical claim.

Upward threshold ladder

SC1 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: no. Establish the proposed aging pathway through functional/lifespan outcomes with specific mediator intervention, not only biomarkers.

SC2 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: yes.

SC2 Ε: “Requires causal effect in constrained contexts, backgrounds, or species.” Satisfied: yes.

SC2 Ζ: “Requires: - Reproducible intervention effects - Mechanistic narrowing - Evidence not reducible to general sickness, caloric reduction, or developmental artifacts” Satisfied: no. Cross Ζ by reproducible mechanistic narrowing across contexts, ruling out diet, sickness and developmental explanations without ignoring internal negative controls.

SC3 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: no. A randomized non-diabetic human study must demonstrate durable prespecified aging-related functional/healthspan trajectory changes, separating single-disease prevention and caloric/weight effects.

Upper ladder: No convergence establishes the full registered claim. Positive narrower results are retained without re-capping an assembled causal set; their scopes and distinct failure modes are stated separately.

Independence: Different publications, laboratories and agents do not automatically form independent causal lines. No nominal Ζ or higher is assigned.

Falsification and pitfalls

Biological clock equals healthspan. Cell-type clocks and monkey clock estimates are not literal years of human rejuvenation.

Same-data reanalysis. The Gehan reanalysis changes interpretation of original ITP data, not independent replication.

Historical combination control. Metformin/rapamycin was compared with earlier rapamycin cohorts rather than a contemporaneous factorial arm.

Indication and eligibility bias. Diabetic treated people versus nondiabetic controls are not randomized metformin-treated nondiabetic people.

Adversarial steelman: above, then below

Case for Δ: DPP prevents diabetes in nondiabetic people, monkey function and aging indicators improve, and selected model lifespan outcomes are positive. This crosses a disease-specific prevention threshold, but not the preregistered conjunctive claim that human general aging slows and broad healthspan improves.

Case for Β: human aging evidence is dominated by biomarkers and observational diabetic survival. Multiple controlled model outcomes and defined pathway dependencies supply partial mechanistic support, making Γ more faithful than an association-only score.

Retain Γ for human geroprotection and Ε for constrained model outcomes. A diabetes-prevention benefit is acknowledged rather than relabeled as no human benefit.

Final score, causal direction and M/S/D

Overall Γ applies to SC3. Context-specific animal function/survival and genuine prevention of diabetes do not establish generalized human aging slowing. The strongest model results are retained at Ε within their tested settings, with dose, timing, sex, diet and statistical boundaries explicit.

For the exact generalized human-aging claim, a causal dependency on metformin-responsive pathways has not been demonstrated. Step 2 is an operational unresolved-role classification, not denial of causal diabetes prevention or model mechanisms; no general-aging primary-driver role is assigned.

Momentum: Mechanistic only. Older-monkey work (PMID39270656), short human mechanistic work (PMID37675817) and model studies pursue mechanisms. DPP is a completed diabetes-prevention programme, not a completed general-aging trial; no pending human geroprotection result with verified timing was identified.

Stability: Stable. No specific pending result with a verified completion trigger was identified in this bounded search; Stable follows the framework definition, not a forecast of permanent truth.

Divergence: Contested; no single implied-level arithmetic. These dimensions do not change level or confidence.

PROPOSED DECISIVE EXPERIMENTS

Conduct a prespecified randomized non-diabetic older-human trial measuring durable clinical/function trajectories, with baseline metabolic strata, nutrition/weight monitoring and mechanistic engagement; keep disease-specific prevention and aging outcomes separate.

Readout: Registered multimorbidity/functional endpoints over adequate follow-up, with pathway engagement. Controls: Matched treatment, allocation/blinding assessment, diet/exercise exposure and weight-related mediation. Supporting: Clinically meaningful durable broad function/healthspan benefit aligned with specific mechanism beyond single-disease prevention. Falsifying: Verified engagement without the registered function/healthspan benefit at adequate power, or prespecified functional deterioration.

KNOWLEDGE GAPS

No selected completed randomized demonstration of slower general human aging.

Model dose, late-life timing and sex boundaries remain unresolved.

Biological-clock shifts need clinical outcome validation.

Food intake, microbiome and disease-specific effects must be separated.

REVIEWER NOTES

Fifty to seventy original primary reports were selected before adjudication. Exact bounded abstract passages and selected body paragraphs are retained with examination receipts. Most papers were not read in full; absent details are limitations, not assumed controls. No independent blind grading, Consensus, Scite or independent scientific peer review was performed for the original review; the dated 9 October 2026 Consensus consistency validation above is a later provenance supplement and is not an independent blinded adjudication. Popularity is editorial interest, not measured demand. Models are a descriptive tournament; their rankings are not independent causal proof. Grades were derived from selected primary evidence after claim registration, without consulting a previous completed grade. The primary-subclaim aggregation is fixed; weakest-link sensitivities remain displayed.

Search leads, reviews, protocols and correction notices do not pad the primary count. Downloaded XML does not earn examination credit. Linked notices remain attached; unexamined correction details limit inference. This is a coordinator source/claim consistency assessment, not independent blinded calibration.

ADVERSARIAL REVIEW AND APPROVAL

Authoring model: Sol 6.1. Adversarial reviewer: Claude Opus 5.5 (Anthropic). Date: 2026-10-14. This edition is the revised copy produced by the 2026-10-09 Consensus-consistency audit; it was reviewed as it now stands, and the block that the revision added was checked against the original records it cites.

Scope of checks. REFERENCE PMIDs verified against PubMed metadata: 61/61 resolve to the stated title, first author, journal and year; DOIs cross-checked for every entry that carries one; no reference carries a retraction, retraction-of-publication or expression-of-concern flag. The four records introduced by the 2026-10-09 supplement were also verified (PMID 42023167, 33428709, 36281624, 42620010). Load-bearing claims spot-checked against PubMed abstracts: 12 (the ITP metformin-alone null and the metformin-plus-rapamycin result with its historical-control caveat; the mouse healthspan/lifespan experiment with the toxic higher dose; the Gehan reanalysis identifying metformin in males only; the Fischer-344 rat null; the monkey aging-clock study; DPP diabetes prevention; the MASTERS muscle-mass result with non-significant strength differences; MET-DIME; the presurgical breast-cancer Ki67 trial with its HOMA interaction; METFORAGING's primary estimate; the animal-lifespan meta-analysis; and the medRxiv frailty trial's Fried and frailty-index results). Scoring logic re-derived against references/hsef-framework.md and rubric 06-metabolism-aging: ladder letter and canonical descriptor, the six universal caps, the pre-registered primary-subclaim aggregation with SC3 named, the causal-role derivation, and the momentum artifact.

Findings.

Four corrections in total (three distinct strings, one of them applied twice).

No level, confidence, role, momentum, stability or divergence value was changed. Final score remains Γ — Mechanistically plausible, partial system support; confidence Moderate; role epiphenomenon; SC2 remains Ε and is reported separately at its own scope.

Rejected findings (checked, no change).

1. Accuracy of the added Consensus-consistency block. Every quantitative claim in it was re-derived from the cited records and is correct, including METFORAGING's randomisation (19/21 of 40), its 35 completers at 96 weeks and its primary PhenoAge estimate (-1.02 years, 95% CI -5.30 to 3.26, p = 0.627); the animal-lifespan meta-analysis finding no significant overall effect in mice or nematodes with a live-OP50 worm subgroup signal; and the medRxiv trial's 145 randomised participants, its year-1 Fried deterioration attributable to the weight-loss item, and its frailty-index change of -0.006 +/- 0.0026 per year, p = 0.0222. The block's handling of the preprint is also correct under the framework: it refuses to let a non-peer-reviewed report cross a threshold and records that a judgement resting on it would force confidence Low. No substantive regression was introduced. Observation only: the block does not mention that the same preprint reports reduced epigenetic age on two clocks; this is an omission of biomarker evidence the review discounts elsewhere, not a misstatement.
2. Aggregation. Pre-registered rule is primary-subclaim with SC3 named; the headline equals SC3 (Γ). Reported alternatives are correct: weakest-link is min(Γ, Ε, Γ) = Γ, and scope-matched is also Γ because SC3 is the only subclaim whose scope is non-diabetic human aging/healthspan (SC1 is pathway-level, SC2 is model systems). No change.
3. Causal role. "Epiphenomenon" is derived at step 2 (no demonstrated causal dependency in either direction for the generalized human-aging claim) and the derivation paragraph says exactly that, while explicitly not denying diabetes prevention or model mechanisms. No change.
4. Momentum. "Mechanistic only" names its artifact (the monkey study PMID 39270656 and the short human mechanistic work PMID 37675817) and correctly declines "Decisive work underway", since no pending human geroprotection result with verified timing was identified. No change.
5. Causal-tally count. The tally states 21 discriminating contrasts and the inventory prints exactly 21 bracketed items; the score card agrees. No change.
6. Reference titles at #30 (PMID 29027899) and #42 (PMID 33953705). PubMed's title field drops the italicised species name and the italicised "via"; the review prints the published titles. Rejected per the italicised-name convention.
7. Reference #14's missing author field. PubMed holds no author list for this record and carries the group name inside the title field, which the review reproduces. Not the dropped-collective-author defect.

Residual limitations. Only 3 of 61 reports were examined at partial-body depth, and those three are exactly the reports whose load-bearing claims need full text (the second mouse strain's non-significant survival result, the ITP analyses, and MASTERS). Two statements could not be re-derived from the records consulted here: the "141 ITT" figure and the BMI-adjusted frailty-index estimate in the medRxiv preprint, and the endpoint hierarchy attributed to the registered protocol (DOI 10.1093/gerona/glz069). The erratum identifiers for PMID 19878986 and PMID 9742977 remain unresolved.

Approval: Following adversarial review and the corrections listed above, the revised document is approved. -- Claude Opus 5.5 (Anthropic), 2026-10-14.

REFERENCES

1. Xu H, Jia C, Cheng C et al. Activation of autophagy attenuates motor deficits and extends lifespan in a C. elegans model of ALS. Free radical biology & medicine. 2022. PMID 35114355. DOI: 10.1016/j.freeradbiomed.2022.01.030. Access: abstract_metadata. Study: PMID35114355.

2. Tezze C, Amendolagine FI, Nogara L et al. A combination of metformin and galantamine exhibits synergistic benefits in the treatment of sarcopenia. JCI insight. 2023. PMID 37551712. DOI: 10.1172/jci.insight.168787. Access: abstract_metadata. Study: PMID37551712.

3. Su WH, Chan CET, Lian T et al. Protection of nuclear DNA by lifespan-extending compounds in the yeast Saccharomyces cerevisiae. Mutation research. 2021. PMID 33578051. DOI: 10.1016/j.mrfmmm.2021.111738. Access: abstract_metadata. Study: PMID33578051.

4. Al Hatem A, Balasubramaniam B, Villhauer A et al. p38 MAPK and MDT-15 mediate SKN-1-dependent metformin-induced protection against mitis group streptococci in Caenorhabditis elegans. GeroScience. 2026. PMID 42503569. DOI: 10.1007/s11357-026-02405-6. Access: abstract_metadata. Study: PMID42503569.

5. Rosell-Díaz M, Petit-Gay A, Molas-Prat C et al. Metformin-induced changes in the gut microbiome and plasma metabolome are associated with cognition in men. Metabolism: clinical and experimental. 2024. PMID 38871078. DOI: 10.1016/j.metabol.2024.155941. Access: abstract_metadata. Study: PMID38871078.

6. de Kreutzenberg SV, Ceolotto G, Cattelan A et al. Metformin improves putative longevity effectors in peripheral mononuclear cells from subjects with prediabetes. A randomized controlled trial. Nutrition, metabolism, and cardiovascular diseases : NMCD. 2015. PMID 25921843. DOI: 10.1016/j.numecd.2015.03.007. Access: abstract_metadata. Study: NCT01765946.

7. Konopka AR, Laurin JL, Schoenberg HM et al. Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults. Aging cell. 2019. PMID 30548390. DOI: 10.1111/acel.12880. Access: abstract_metadata. Study: PMID30548390.

8. Hazuda HP, Pan Q, Florez H et al. Association of Intensive Lifestyle and Metformin Interventions With Frailty in the Diabetes Prevention Program Outcomes Study. The journals of gerontology. Series A, Biological sciences and medical sciences. 2021. PMID 33428709. DOI: 10.1093/gerona/glaa295. Access: abstract_metadata. Study: DPP_DPPOS.

9. Knowler WC, Doherty L, Edelstein SL et al. Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial. The lancet. Diabetes & endocrinology. 2025. PMID 40311647. DOI: 10.1016/S2213-8587(25)00022-1. Access: abstract_metadata. Study: DPP_DPPOS.

10. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. The New England journal of medicine. 2002. PMID 11832527. DOI: 10.1056/NEJMoa012512. Access: abstract_metadata. Study: DPP_DPPOS.

11. Malin SK, Heiston EM, Battillo DJ et al. Metformin Blunts Vascular Insulin Sensitivity After Exercise Training in Adults at Risk for Metabolic Syndrome. The Journal of clinical endocrinology and metabolism. 2026. PMID 41160096. DOI: 10.1210/clinem/dgaf551. Access: abstract_metadata. Study: PMID41160096.

12. Diabetes Prevention Program Research Group, Knowler WC, Fowler SE et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet (London, England). 2009. PMID 19878986. DOI: 10.1016/S0140-6736(09)61457-4. Access: abstract_metadata. Study: DPP_DPPOS.

13. Holman RR, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in type 2 diabetes. The New England journal of medicine. 2008. PMID 18784090. DOI: 10.1056/NEJMoa0806470. Access: abstract_metadata. Study: UKPDS.

14. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet (London, England). 1998. PMID 9742977. Access: abstract_metadata. Study: UKPDS.

15. Cheng YY, Leu HB, Chen TJ et al. Metformin-inclusive therapy reduces the risk of stroke in patients with diabetes: a 4-year follow-up study. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association. 2014. PMID 24119365. DOI: 10.1016/j.jstrokecerebrovasdis.2013.09.001. Access: abstract_metadata. Study: PMID24119365.

16. Bensimon L, Yin H, Suissa S et al. The use of metformin in patients with prostate cancer and the risk of death. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2014. PMID 25017246. DOI: 10.1158/1055-9965.EPI-14-0056. Access: abstract_metadata. Study: PMID25017246.

17. Roussel R, Travert F, Pasquet B et al. Metformin use and mortality among patients with diabetes and atherothrombosis. Archives of internal medicine. 2010. PMID 21098347. DOI: 10.1001/archinternmed.2010.409. Access: abstract_metadata. Study: PMID21098347.

18. Yang Y, Lu X, Liu N et al. Metformin decelerates aging clock in male monkeys. Cell. 2024. PMID 39270656. DOI: 10.1016/j.cell.2024.08.021. Access: abstract_metadata. Study: PMID39270656.

19. Ma T, Tian X, Zhang B et al. Low-dose metformin targets the lysosomal AMPK pathway through PEN2. Nature. 2022. PMID 35197629. DOI: 10.1038/s41586-022-04431-8. Access: abstract_metadata. Study: PMID35197629.

20. Ren C, Jin J, Li C et al. Metformin inactivates the cGAS-STING pathway through autophagy and suppresses senescence in nucleus pulposus cells. Journal of cell science. 2022. PMID 35722742. DOI: 10.1242/jcs.259738. Access: abstract_metadata. Study: PMID35722742.

21. Bharath LP, Agrawal M, McCambridge G et al. Metformin Enhances Autophagy and Normalizes Mitochondrial Function to Alleviate Aging-Associated Inflammation. Cell metabolism. 2020. PMID 32402267. DOI: 10.1016/j.cmet.2020.04.015. Access: abstract_metadata. Study: PMID32402267.

22. Cabreiro F, Au C, Leung KY et al. Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism. Cell. 2013. PMID 23540700. DOI: 10.1016/j.cell.2013.02.035. Access: abstract_metadata. Study: PMID23540700.

23. Neumann B, Baror R, Zhao C et al. Metformin Restores CNS Remyelination Capacity by Rejuvenating Aged Stem Cells. Cell stem cell. 2019. PMID 31585093. DOI: 10.1016/j.stem.2019.08.015. Access: abstract_metadata. Study: PMID31585093.

24. Li C, Mu N, Gu C et al. Metformin mediates cardioprotection against aging-induced ischemic necroptosis. Aging cell. 2020. PMID 31944526. DOI: 10.1111/acel.13096. Access: abstract_metadata. Study: PMID31944526.

25. Landry DA, Yakubovich E, Cook DP et al. Metformin prevents age-associated ovarian fibrosis by modulating the immune landscape in female mice. Science advances. 2022. PMID 36054356. DOI: 10.1126/sciadv.abq1475. Access: abstract_metadata. Study: PMID36054356.

26. Horiuchi T, Sakata N, Narumi Y et al. Metformin directly binds the alarmin HMGB1 and inhibits its proinflammatory activity. The Journal of biological chemistry. 2017. PMID 28373282. DOI: 10.1074/jbc.M116.769380. Access: abstract_metadata. Study: PMID28373282.

27. Kim H, Yu MR, Lee H et al. Metformin inhibits chronic kidney disease-induced DNA damage and senescence of mesenchymal stem cells. Aging cell. 2021. PMID 33524231. DOI: 10.1111/acel.13317. Access: abstract_metadata. Study: PMID33524231.

28. Kumazawa T, Xu Y, Wang Y et al. Metformin inhibits nuclear egress of chromatin fragments in senescence and aging. Nature aging. 2026. PMID 41545663. DOI: 10.1038/s43587-025-01048-0. Access: abstract_metadata. Study: PMID41545663.

29. Matsiukevich D, Piraino G, Lahni P et al. Metformin ameliorates gender-and age-dependent hemodynamic instability and myocardial injury in murine hemorrhagic shock. Biochimica et biophysica acta. Molecular basis of disease. 2017. PMID 28579457. DOI: 10.1016/j.bbadis.2017.05.027. Access: abstract_metadata. Study: PMID28579457.

30. Chen J, Ou Y, Li Y et al. Metformin extends C. elegans lifespan through lysosomal pathway. eLife. 2017. PMID 29027899. DOI: 10.7554/eLife.31268. Access: abstract_metadata. Study: PMID29027899.

31. Emelyanova L, Bai X, Yan Y et al. Biphasic effect of metformin on human cardiac energetics. Translational research : the journal of laboratory and clinical medicine. 2021. PMID 33045408. DOI: 10.1016/j.trsl.2020.10.002. Access: abstract_metadata. Study: PMID33045408.

32. Suzuta S, Nishida H, Ozaki M et al. Metformin suppresses progression of muscle aging via activation of the AMP kinase-mediated pathways in Drosophila adults. European review for medical and pharmacological sciences. 2022. PMID 36394755. DOI: 10.26355/eurrev_202211_30158. Access: abstract_metadata. Study: PMID36394755.

33. Yi G, He Z, Zhou X et al. Low concentration of metformin induces a p53-dependent senescence in hepatoma cells via activation of the AMPK pathway. International journal of oncology. 2013. PMID 23982736. DOI: 10.3892/ijo.2013.2077. Access: abstract_metadata. Study: PMID23982736.

34. Sung JY, Kim SG, Kang YJ et al. Metformin mitigates stress-induced premature senescence by upregulating AMPKα at Ser485 phosphorylation induced SIRT3 expression and inactivating mitochondrial oxidants. Mechanisms of ageing and development. 2022. PMID 35863470. DOI: 10.1016/j.mad.2022.111708. Access: abstract_metadata. Study: PMID35863470.

35. Zhao P, Sui BD, Liu N et al. Anti-aging pharmacology in cutaneous wound healing: effects of metformin, resveratrol, and rapamycin by local application. Aging cell. 2017. PMID 28677234. DOI: 10.1111/acel.12635. Access: abstract_metadata. Study: PMID28677234.

36. Reid JJ, Linden MA, Peelor FF et al. Brain Protein Synthesis Rates in the UM-HET3 Mouse Following Treatment With Rapamycin or Rapamycin With Metformin. The journals of gerontology. Series A, Biological sciences and medical sciences. 2020. PMID 30864661. DOI: 10.1093/gerona/glz069. Access: abstract_metadata. Study: PMID30864661.

37. Corley MJ, Pang APS, Shikuma CM et al. Cell-type specific impact of metformin on monocyte epigenetic age reversal in virally suppressed older people living with HIV. Aging cell. 2024. PMID 37675817. DOI: 10.1111/acel.13926. Access: abstract_metadata. Study: PMID37675817.

38. Martin-Montalvo A, Mercken EM, Mitchell SJ et al. Metformin improves healthspan and lifespan in mice. Nature communications. 2013. PMID 23900241. DOI: 10.1038/ncomms3192. Access: full_text_partial. Study: PMID23900241.

39. Tai S, Sun J, Zhou Y et al. Metformin suppresses vascular smooth muscle cell senescence by promoting autophagic flux. Journal of advanced research. 2022. PMID 36328749. DOI: 10.1016/j.jare.2021.12.009. Access: abstract_metadata. Study: PMID36328749.

40. Chen Q, Zhang H, Yang Y et al. Metformin Attenuates UVA-Induced Skin Photoaging by Suppressing Mitophagy and the PI3K/AKT/mTOR Pathway. International journal of molecular sciences. 2022. PMID 35805987. DOI: 10.3390/ijms23136960. Access: abstract_metadata. Study: PMID35805987.

41. Mahmassani ZS, McKenzie AI, Petrocelli JJ et al. Short-term metformin ingestion by healthy older adults improves myoblast function. American journal of physiology. Cell physiology. 2021. PMID 33406027. DOI: 10.1152/ajpcell.00469.2020. Access: abstract_metadata. Study: PMID33406027.

42. Hartwig J, Loebel M, Steiner S et al. Metformin Attenuates ROS via FOXO3 Activation in Immune Cells. Frontiers in immunology. 2021. PMID 33953705. DOI: 10.3389/fimmu.2021.581799. Access: abstract_metadata. Study: PMID33953705.

43. Cuyàs E, Verdura S, Llorach-Pares L et al. Metformin directly targets the H3K27me3 demethylase KDM6A/UTX. Aging cell. 2018. PMID 29740925. DOI: 10.1111/acel.12772. Access: abstract_metadata. Study: PMID29740925.

44. Xiao Y, Liu F, Li S et al. Metformin promotes innate immunity through a conserved PMK-1/p38 MAPK pathway. Virulence. 2020. PMID 31851866. DOI: 10.1080/21505594.2019.1706305. Access: abstract_metadata. Study: PMID31851866.

45. Garg G, Singh S, Singh AK et al. Metformin Alleviates Altered Erythrocyte Redox Status During Aging in Rats. Rejuvenation research. 2017. PMID 27185159. DOI: 10.1089/rej.2016.1826. Access: abstract_metadata. Study: PMID27185159.

46. Smith DL, Elam CF, Mattison JA et al. Metformin supplementation and life span in Fischer-344 rats. The journals of gerontology. Series A, Biological sciences and medical sciences. 2010. PMID 20304770. DOI: 10.1093/gerona/glq033. Access: abstract_metadata. Study: PMID20304770.

47. Feng X, Pan J, Li J et al. Metformin attenuates cartilage degeneration in an experimental osteoarthritis model by regulating AMPK/mTOR. Aging. 2020. PMID 31945013. DOI: 10.18632/aging.102635. Access: abstract_metadata. Study: PMID31945013.

48. Strong R, Miller RA, Antebi A et al. Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α-glucosidase inhibitor or a Nrf2-inducer. Aging cell. 2016. PMID 27312235. DOI: 10.1111/acel.12496. Access: full_text_partial. Study: ITP_C2011.

49. Espada L, Dakhovnik A, Chaudhari P et al. Loss of metabolic plasticity underlies metformin toxicity in aged Caenorhabditis elegans. Nature metabolism. 2020. PMID 33139960. DOI: 10.1038/s42255-020-00307-1. Access: abstract_metadata. Study: PMID33139960.

50. Weiss R, Fernandez E, Liu Y et al. Metformin reduces glucose intolerance caused by rapamycin treatment in genetically heterogeneous female mice. Aging. 2018. PMID 29579736. DOI: 10.18632/aging.101401. Access: abstract_metadata. Study: PMID29579736.

51. Jiang N, Gelfond J, Liu Q et al. The Gehan test identifies life-extending compounds overlooked by the log-rank test in the NIA Interventions Testing Program: Metformin, Enalapril, caffeic acid phenethyl ester, green tea extract, and 17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride. GeroScience. 2024. PMID 38630424. DOI: 10.1007/s11357-024-01161-9. Access: abstract_metadata. Study: ITP_C2011.

52. Gorgich EAC, Parsaie H, Yarmand S et al. Long-term administration of metformin ameliorates age-dependent oxidative stress and cognitive function in rats. Behavioural brain research. 2021. PMID 33965434. DOI: 10.1016/j.bbr.2021.113343. Access: abstract_metadata. Study: PMID33965434.

53. Cameron AR, Morrison VL, Levin D et al. Anti-Inflammatory Effects of Metformin Irrespective of Diabetes Status. Circulation research. 2016. PMID 27418629. DOI: 10.1161/CIRCRESAHA.116.308445. Access: abstract_metadata. Study: NCT00473876.

54. Bonanni B, Puntoni M, Cazzaniga M et al. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012. PMID 22564993. DOI: 10.1200/JCO.2011.39.3769. Access: abstract_metadata. Study: PMID22564993.

55. Hosono K, Endo H, Takahashi H et al. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer prevention research (Philadelphia, Pa.). 2010. PMID 20810669. DOI: 10.1158/1940-6207.CAPR-10-0186. Access: abstract_metadata. Study: PMID20810669.

56. Paolisso G, Amato L, Eccellente R et al. Effect of metformin on food intake in obese subjects. European journal of clinical investigation. 1998. PMID 9693934. DOI: 10.1046/j.1365-2362.1998.00304.x. Access: abstract_metadata. Study: PMID9693934.

57. Nanni O, Amadori D, De Censi A et al. Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial. Breast cancer research and treatment. 2019. PMID 30536182. DOI: 10.1007/s10549-018-05070-2. Access: abstract_metadata. Study: PMID30536182.

58. Ladeiras-Lopes R, Sampaio F, Leite S et al. Metformin in non-diabetic patients with metabolic syndrome and diastolic dysfunction: the MET-DIME randomized trial. Endocrine. 2021. PMID 33830437. DOI: 10.1007/s12020-021-02687-0. Access: abstract_metadata. Study: PMID33830437.

59. Bannister CA, Holden SE, Jenkins-Jones S et al. Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. Diabetes, obesity & metabolism. 2014. PMID 25041462. DOI: 10.1111/dom.12354. Access: abstract_metadata. Study: PMID25041462.

60. Walton RG, Dungan CM, Long DE et al. Metformin blunts muscle hypertrophy in response to progressive resistance exercise training in older adults: A randomized, double-blind, placebo-controlled, multicenter trial: The MASTERS trial. Aging cell. 2019. PMID 31557380. DOI: 10.1111/acel.13039. Access: full_text_partial. Study: NCT02308228.

61. Stevenson-Hoare J, Leonenko G, Escott-Price V. Comparison of long-term effects of metformin on longevity between people with type 2 diabetes and matched non-diabetic controls. BMC public health. 2023. PMID 37131166. DOI: 10.1186/s12889-023-15764-y. Access: abstract_metadata. Study: PMID37131166.

Source-specific evidence cards

[1] Activation of autophagy attenuates motor deficits and extends lifespan in a C. elegans model of ALS.

Shows: Metformin improved survival/motor outcomes in an ALS worm model with pathway dependencies.

Does not show: A syndromic worm model does not establish general aging or human healthspan.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[2] A combination of metformin and galantamine exhibits synergistic benefits in the treatment of sarcopenia.

Shows: Metformin/galantamine combinations improved selected muscle and survival phenotypes.

Does not show: Combination effects cannot be assigned to metformin alone or generalized to humans.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[3] Protection of nuclear DNA by lifespan-extending compounds in the yeast Saccharomyces cerevisiae.

Shows: Metformin affected yeast protection during DNA stress.

Does not show: Stress survival is not organismal aging-rate or human functional benefit.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[4] p38 MAPK and MDT-15 mediate SKN-1-dependent metformin-induced protection against mitis group streptococci in Caenorhabditis elegans.

Shows: Metformin affected worm bacterial-stress resistance through tested pathways.

Does not show: Infection resistance is distinct from aging and organism-wide healthspan.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[5] Metformin-induced changes in the gut microbiome and plasma metabolome are associated with cognition in men.

Shows: Diabetic cohorts showed sex-related microbiome/cognition associations with metformin.

Does not show: Nonrandomized diabetic exposure cannot establish non-diabetic aging effects.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[6] Metformin improves putative longevity effectors in peripheral mononuclear cells from subjects with prediabetes. A randomized controlled trial.

Shows: A prediabetes trial altered PBMC/metabolic molecular measures.

Does not show: Biomarkers do not establish slower aging or generalized healthspan.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[7] Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults.

Shows: Metformin attenuated selected aerobic-training and mitochondrial adaptations in older adults.

Does not show: This does not prove universal harm or absence of benefits outside the exercise context.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[8] Association of Intensive Lifestyle and Metformin Interventions With Frailty in the Diabetes Prevention Program Outcomes Study.

Shows: DPPOS frailty analyses favored lifestyle but not metformin.

Does not show: Prediabetic enrollment and endpoint context do not resolve every aging outcome.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[9] Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial.

Shows: Long DPP follow-up retained an attenuated diabetes-prevention effect, differing by age.

Does not show: Same study family; prevention in prediabetes does not establish a slower generalized aging trajectory. An erratum is attached.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. ErratumIn: PMID40319894. Subclaims: SC1, SC2, SC3.

[10] Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.

Shows: DPP randomized metformin and lifestyle both prevented diabetes in high-risk nondiabetic participants.

Does not show: A real disease-specific preventive effect is not proof that metformin slows general aging.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[11] Metformin Blunts Vascular Insulin Sensitivity After Exercise Training in Adults at Risk for Metabolic Syndrome.

Shows: Metformin blunted selected exercise-related vascular adaptations.

Does not show: Treatment-by-exercise context is not universal longevity harm.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[12] 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.

Shows: DPP follow-up found persistent but attenuated diabetes prevention.

Does not show: Same parent randomization and subsequent treatment changes limit independent-line counting.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. Erratum in: PMID not supplied. Subclaims: SC1, SC2, SC3.

[13] 10-year follow-up of intensive glucose control in type 2 diabetes.

Shows: UKPDS follow-up supported selected long-term benefits after diabetes treatment.

Does not show: Established diabetes and legacy treatment effects do not establish non-diabetic geroprotection.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[14] Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

Shows: UKPDS metformin improved selected diabetic outcomes with differing results in combination arms.

Does not show: Diabetic disease management and combination context cannot be substituted for general aging.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. Erratum in: PMID not supplied. Subclaims: SC1, SC2, SC3.

[15] Metformin-inclusive therapy reduces the risk of stroke in patients with diabetes: a 4-year follow-up study.

Shows: A diabetic observational cohort associated metformin with fewer strokes.

Does not show: Confounding by indication and eligibility remain; no nondiabetic randomized aging test.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[16] The use of metformin in patients with prostate cancer and the risk of death.

Shows: A diabetic prostate-cancer cohort did not show a clear mortality association benefit.

Does not show: Disease-specific observational null is not a decisive aging falsifier.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[17] Metformin use and mortality among patients with diabetes and atherothrombosis.

Shows: Metformin associated with lower mortality in a diabetic atherothrombotic cohort.

Does not show: Treatment selection and diabetes context remain.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[18] Metformin decelerates aging clock in male monkeys.

Shows: Metformin-treated older male monkeys showed selected functional, structural and aging-indicator changes.

Does not show: Sex-specific nonhuman context and aging-clock shifts are not demonstrated human lifespan extension or literal years rejuvenated.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[19] Low-dose metformin targets the lysosomal AMPK pathway through PEN2.

Shows: PEN2/ATP6AP1 experiments identified a lysosomal metformin/AMPK mechanism with model genetic dependencies.

Does not show: Target/pathway causality is not organism-wide human aging causality.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[20] Metformin inactivates the cGAS-STING pathway through autophagy and suppresses senescence in nucleus pulposus cells.

Shows: Metformin altered autophagy/STING and disc-senescence phenotypes in models.

Does not show: Disease/model endpoints cannot establish general healthspan.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[21] Metformin Enhances Autophagy and Normalizes Mitochondrial Function to Alleviate Aging-Associated Inflammation.

Shows: Metformin changed aged-human T-cell function ex vivo.

Does not show: Ex vivo immune rescue is not a treated-human aging trajectory.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[22] Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism.

Shows: Metformin changed worm lifespan through bacterial metabolism and methionine-related context.

Does not show: Diet and bacterial-strain dependence challenge a uniform direct host-aging mechanism.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[23] Metformin Restores CNS Remyelination Capacity by Rejuvenating Aged Stem Cells.

Shows: Metformin restored aged rodent oligodendrocyte precursor/remyelination responses.

Does not show: Lesion repair is functional but does not establish global aging or human healthspan.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[24] Metformin mediates cardioprotection against aging-induced ischemic necroptosis.

Shows: Metformin altered aged-mouse ischemic injury and necroptosis-related outcomes.

Does not show: Acute injury survival is not general longevity.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[25] Metformin prevents age-associated ovarian fibrosis by modulating the immune landscape in female mice.

Shows: Metformin affected aged mouse ovarian fibrosis/immune measures.

Does not show: Tissue markers alone cannot establish whole-organism healthspan.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[26] Metformin directly binds the alarmin HMGB1 and inhibits its proinflammatory activity.

Shows: Metformin interacted with HMGB1 and affected inflammatory model outcomes.

Does not show: Binding and acute inflammation do not identify the primary aging mechanism.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[27] Metformin inhibits chronic kidney disease-induced DNA damage and senescence of mesenchymal stem cells.

Shows: Metformin preconditioning altered CKD-related mesenchymal-cell senescence/repair measures.

Does not show: Cell preparation and repair context differ from systemic human treatment.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[28] Metformin inhibits nuclear egress of chromatin fragments in senescence and aging.

Shows: CCF/ALIX pathway work linked metformin/AMPK to aged-mouse intestinal inflammation.

Does not show: Local inflammation and senescence markers are not generalized human functional benefit.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[29] Metformin ameliorates gender-and age-dependent hemodynamic instability and myocardial injury in murine hemorrhagic shock.

Shows: Metformin affected shock outcomes differently by age and sex in mice.

Does not show: Acute injury and context-dependent survival do not prove generalized geroprotection.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[30] Metformin extends C. elegans lifespan through lysosomal pathway.

Shows: Worm genetic work linked metformin longevity effects to lysosomal AMPK/TOR signaling.

Does not show: Pathway dependence in a model does not establish human mechanism necessity.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[31] Biphasic effect of metformin on human cardiac energetics.

Shows: Human cardiomyocyte experiments found concentration-dependent metabolic responses to metformin.

Does not show: In vitro exposure levels and metabolic endpoints cannot establish clinical aging benefit.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[32] Metformin suppresses progression of muscle aging via activation of the AMP kinase-mediated pathways in Drosophila adults.

Shows: Fly experiments linked metformin to muscle function/lifespan and AMPK/TOR pathways.

Does not show: Species and model context limit inference to humans.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[33] Low concentration of metformin induces a p53-dependent senescence in hepatoma cells via activation of the AMPK pathway.

Shows: Metformin induced senescence-related effects in hepatoma cells.

Does not show: Anticancer cell effects oppose a simplistic universal senescence-erasing description, not all geroprotection.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[34] Metformin mitigates stress-induced premature senescence by upregulating AMPKα at Ser485 phosphorylation induced SIRT3 expression and inactivating mitochondrial oxidants.

Shows: Metformin altered stressed vascular-cell senescence via AMPK/SIRT3-related signaling.

Does not show: Cellular rescue is not organismal functional benefit.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[35] Anti-aging pharmacology in cutaneous wound healing: effects of metformin, resveratrol, and rapamycin by local application.

Shows: Topical metformin improved selected aged-rodent wound-healing outcomes.

Does not show: Local route and injury context differ from generalized aging treatment; an erratum is attached.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. ErratumIn: PMID35112450. Subclaims: SC1, SC2.

[36] Brain Protein Synthesis Rates in the UM-HET3 Mouse Following Treatment With Rapamycin or Rapamycin With Metformin.

Shows: Rapamycin/metformin combinations altered brain proteins with age/sex dependence.

Does not show: Combination biomarker effects do not isolate metformin longevity or independent ITP replication.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[37] Cell-type specific impact of metformin on monocyte epigenetic age reversal in virally suppressed older people living with HIV.

Shows: Metformin in normoglycemic people with HIV altered selected monocyte aging-clock measures.

Does not show: Cell-type-specific clock shifts and disease context do not establish human healthspan.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[38] Metformin improves healthspan and lifespan in mice.

Shows: Metformin extended lifespan and improved fitness in a defined male-mouse experiment while a higher exposure shortened survival.

Does not show: The second strain's survival result was nonsignificant; concentration, sex and context boundaries prevent generalizing to human aging.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 0:Results:paragraph0, 0:Results:paragraph3. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[39] Metformin suppresses vascular smooth muscle cell senescence by promoting autophagic flux.

Shows: Metformin affected vascular stiffness and senescence-related model measures.

Does not show: Context-specific vascular outcomes do not establish human geroprotection; an erratum is attached.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. ErratumIn: PMID42379936. Subclaims: SC1, SC2.

[40] Metformin Attenuates UVA-Induced Skin Photoaging by Suppressing Mitophagy and the PI3K/AKT/mTOR Pathway.

Shows: Metformin protected selected UVA-related cell/mouse photoaging measures.

Does not show: Photodamage is not whole-organism aging trajectory.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[41] Short-term metformin ingestion by healthy older adults improves myoblast function.

Shows: A short older-human exposure study changed myoblast function and inflammatory signatures.

Does not show: Small short-term tissue assays do not demonstrate slower aging or durable clinical benefit.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[42] Metformin Attenuates ROS via FOXO3 Activation in Immune Cells.

Shows: FOXO3/immune-cell perturbations implicated a pathway in metformin-related ROS responses.

Does not show: Cell dependency and oxidative measures are not lifespan/healthspan proof.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[43] Metformin directly targets the H3K27me3 demethylase KDM6A/UTX.

Shows: Metformin affected KDM6A/chromatin measures in biochemical and model experiments.

Does not show: Exposure levels and epigenetic endpoints do not establish clinical aging-rate change.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[44] Metformin promotes innate immunity through a conserved PMK-1/p38 MAPK pathway.

Shows: Metformin affected innate-immune infection resistance through p38-related pathways.

Does not show: Infection stress resistance is not demonstrated generalized longevity.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[45] Metformin Alleviates Altered Erythrocyte Redox Status During Aging in Rats.

Shows: Rat metformin experiments altered redox markers.

Does not show: Redox biomarkers alone cannot cross the aging causal threshold.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[46] Metformin supplementation and life span in Fischer-344 rats.

Shows: Fischer-344 rat survival did not show a metformin longevity benefit under tested conditions.

Does not show: A regimen-specific null constrains robustness rather than proving all metformin aging effects absent.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[47] Metformin attenuates cartilage degeneration in an experimental osteoarthritis model by regulating AMPK/mTOR.

Shows: Metformin reduced cartilage damage in an injury-induced mouse osteoarthritis model.

Does not show: Postinjury tissue benefit does not demonstrate broad aging prevention.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[48] Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α-glucosidase inhibitor or a Nrf2-inducer.

Shows: ITP's original analysis found no statistically significant metformin-alone lifespan benefit; combination survival improved.

Does not show: Later reanalysis detected a male early-survival signal; historical rapamycin controls do not isolate combination synergy.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Results:paragraph6, 1:Results:paragraph9. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[49] Loss of metabolic plasticity underlies metformin toxicity in aged Caenorhabditis elegans.

Shows: Late-life metformin shortened worm survival in a metabolic-plasticity context.

Does not show: Age-dependent model toxicity is not direct evidence of human lifespan harm.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[50] Metformin reduces glucose intolerance caused by rapamycin treatment in genetically heterogeneous female mice.

Shows: Metformin/rapamycin affected female-mouse glucose tolerance.

Does not show: Combination and metabolic endpoint do not establish metformin-alone longevity.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[51] The Gehan test identifies life-extending compounds overlooked by the log-rank test in the NIA Interventions Testing Program: Metformin, Enalapril, caffeic acid phenethyl ester, green tea extract, and 17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride.

Shows: A Gehan-test reanalysis detected early male survival effects in previously reported ITP data.

Does not show: Same cohort, altered statistical weighting and retrospective analysis are not independent prospective replication.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[52] Long-term administration of metformin ameliorates age-dependent oxidative stress and cognitive function in rats.

Shows: Rat experiments supported selected memory/function and redox effects.

Does not show: Species and endpoint context do not establish human aging slowing.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[53] Anti-Inflammatory Effects of Metformin Irrespective of Diabetes Status.

Shows: Model and nondiabetic heart-failure analyses supported selected anti-inflammatory effects.

Does not show: Inflammatory measures and disease context do not establish generalized healthspan.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[54] Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial.

Shows: Presurgical breast-cancer metformin did not improve overall Ki67, with exploratory insulin-resistance heterogeneity.

Does not show: Subgroup interaction and a proliferation surrogate do not establish cancer prevention or aging benefit.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[55] Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial.

Shows: A small nondiabetic trial reduced a colorectal aberrant-crypt-foci surrogate.

Does not show: A short surrogate trial is not cancer-incidence or lifespan proof.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[56] Effect of metformin on food intake in obese subjects.

Shows: Metformin reduced food intake and weight in nondiabetic obesity.

Does not show: Caloric intake is a competing mediator and cannot be assumed aging-specific benefit.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[57] Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial.

Shows: MYME did not improve breast-cancer progression-free survival with metformin addition.

Does not show: Chemotherapy combination in cancer is not a generalized aging intervention.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[58] Metformin in non-diabetic patients with metabolic syndrome and diastolic dysfunction: the MET-DIME randomized trial.

Shows: MET-DIME improved selected diastolic Doppler measures without a clear peak-VO2 or SF36 difference.

Does not show: Imaging/physiology changes are not demonstrated broad functional healthspan.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[59] Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls.

Shows: An observational comparison reported survival advantages for metformin-treated diabetics over matched nondiabetic controls.

Does not show: Treatment eligibility, diabetes differences and censoring can create selection bias; controls did not receive randomized metformin.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[60] Metformin blunts muscle hypertrophy in response to progressive resistance exercise training in older adults: A randomized, double-blind, placebo-controlled, multicenter trial: The MASTERS trial.

Shows: MASTERS found less exercise-induced muscle-mass gain with metformin in older adults.

Does not show: Strength differences were trends without statistical significance; muscle adaptation is not all aging outcomes. An erratum is attached.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:RESULTS:paragraph8, 1:RESULTS:paragraph10. No complete-paper or supplement audit claimed. ErratumIn: PMID32141718. Subclaims: SC1, SC2, SC3.

[61] Comparison of long-term effects of metformin on longevity between people with type 2 diabetes and matched non-diabetic controls.

Shows: Longer UK cohort comparison did not sustain diabetic-metformin users' apparent survival advantage over nondiabetic controls.

Does not show: Diabetes burden and nonrandomized treatment prevent attributing shorter survival to drug toxicity.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

Documentary record

Every grade on this site is reproducible from its record. The files below are the posted edition exactly as assessed.

• ADVERSARIAL_REVIEW.md
• SHA256.txt
• adversarial-findings.json
• codex-correction-provenance.json
• consensus-addendum.md
• consensus-validation.json
• edition-approval-audit.json
• metformin-geroprotection.review.md
• metformin-geroprotection.scorecard.json
• reader-summary.json
• validation-report.json
• validation-round2-2026-10-14.json
• validation.txt

Sources: 61 · load-bearing claims: 65 · verified: 65 · unverified: 0 · contradicted: 0 · schema 5.3